Ejaculation Clinical Trial
Official title:
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study To Assess The Efficacy and Safety Of Oral UK-390,957 In Men With Premature Ejaculation
Verified date | November 2012 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Assessment of efficacy and safety UK-390,957
Status | Completed |
Enrollment | 138 |
Est. completion date | July 2005 |
Est. primary completion date | July 2005 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Premature ejaculation as defined by DSM-IV Exclusion Criteria: - History of erectile dysfunction |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Pfizer Investigational Site | Malvern | Victoria |
Australia | Pfizer Investigational Site | St Leonards | New South Wales |
Canada | Pfizer Investigational Site | Barrie | Ontario |
Canada | Pfizer Investigational Site | London | Ontario |
Canada | Pfizer Investigational Site | Toronto | Ontario |
Canada | Pfizer Investigational Site | Victoria | British Columbia |
United Kingdom | Pfizer Investigational Site | Devon | |
United Kingdom | Pfizer Investigational Site | Nr Lichfield | Staffordshire |
United States | Pfizer Investigational Site | Beachwood | Ohio |
United States | Pfizer Investigational Site | Birmingham | Alabama |
United States | Pfizer Investigational Site | Dallas | Texas |
United States | Pfizer Investigational Site | Houston | Texas |
United States | Pfizer Investigational Site | Kansas City | Missouri |
United States | Pfizer Investigational Site | Knoxville | Tennessee |
United States | Pfizer Investigational Site | Metairie | Louisiana |
United States | Pfizer Investigational Site | Milwaukee | Wisconsin |
United States | Pfizer Investigational Site | New York | New York |
United States | Pfizer Investigational Site | Portland | Oregon |
United States | Pfizer Investigational Site | San Bernardino | California |
United States | Pfizer Investigational Site | Washington | Missouri |
United States | Pfizer Investigational Site | Watertown | Massachusetts |
United States | Pfizer Investigational Site | Williamsville | New York |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Australia, Canada, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of efficacy and safety | |||
Secondary | Assessment of quality of sexual life |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01021670 -
An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride
|
Phase 4 | |
Completed |
NCT00210613 -
A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation
|
Phase 3 | |
Completed |
NCT00211107 -
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.
|
Phase 3 | |
Completed |
NCT00219609 -
Assessment Of Safety Of UK-390,957
|
Phase 2/Phase 3 | |
Terminated |
NCT02918227 -
Exploration of Ejaculation Changing Mechanism After Surgery for Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00219583 -
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation
|
Phase 2/Phase 3 | |
Completed |
NCT00143117 -
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
|
Phase 2/Phase 3 | |
Completed |
NCT01366664 -
A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
|
Phase 1 | |
Completed |
NCT01230762 -
An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation
|
Phase 3 | |
Completed |
NCT00211094 -
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
|
Phase 3 |